GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Land And Improvements

Cellectis (XPAR:ALCLS) Land And Improvements : €17.01 Mil (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Land And Improvements?

Cellectis's land and improvements for the quarter that ended in Jun. 2024 was €17.01 Mil.

Cellectis's quarterly land and improvements declined from Dec. 2023 (€17.01 Mil) to Mar. 2024 (€16.74 Mil) but then increased from Mar. 2024 (€16.74 Mil) to Jun. 2024 (€17.01 Mil).

Cellectis's annual land and improvements declined from Dec. 2021 (€19.85 Mil) to Dec. 2022 (€16.75 Mil) but then increased from Dec. 2022 (€16.75 Mil) to Dec. 2023 (€17.01 Mil).


Cellectis Land And Improvements Historical Data

The historical data trend for Cellectis's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Land And Improvements Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.05 18.51 19.85 16.75 17.01

Cellectis Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.79 16.64 17.01 16.74 17.01

Cellectis Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Cellectis Business Description

Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines